Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial

Source: International Congress 2022 – Exhaled/blood biomarkers and lung function testing in chronic airway diseases

Session: Exhaled/blood biomarkers and lung function testing in chronic airway diseases
Session type: Thematic Poster
Number: 3191

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. De Prado Gomez (Reading, United Kingdom), I. Pavord (Oxford, United Kingdom), W. Busse (WI, United States), C. Brightling (Leicester, United Kingdom), M. Wechsler (Grosshansdorf, Germany), K. Rabe (Keil, United Kingdom), M. Zhang (NJ, United States), J. Xing (NJ, United States), J. Jacob-Nara (NJ, United States), P. J Rowe (NJ, United States). Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial. 3191

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.